Safety of Recombinant HIV Vaccines in HIV Infected Young Adults on Stable Therapy - Full Text View

Purpose

The purpose of this study is to determine the safety of two recombinant HIV vaccines in HIV infected young adults on stable anti-HIV therapy.

Condition	Intervention	Phase
HIV Infections	Biological: rMVA-HIV (env/gag [TBC-M358] + tat/rev/nef-RT [TBC-M335)]) Biological: rFPV-HIV (env/gag [TBC-F357] + tat/rev/nef-RT [TBC-F349])	Phase 1


Study Type:	Interventional
Study Design:	Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	A Phase I, Open-Label Study to Evaluate the Safety and Tolerability of Recombinant HIV-1 Vaccines in HIV-1 Infected Young Adults With Control of HIV-1 Replication and on Stable Highly Active Antiretroviral Therapy (HAART)

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS

U.S. FDA Resources

Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Primary Outcome Measures:

Development of any adverse events of Grade 3 or higher [ Time Frame: Throughout study ]
Development of adverse events of Grade 3 or higher attributed to the study vaccines [ Time Frame: Throughout study ]
Viral breakthrough to greater than 1,000 copies/ml [ Time Frame: During the first 24 weeks of study ]


Enrollment:	20
Study Completion Date:	February 2009

Arms	Assigned Interventions
Experimental: 1 All participants in this study will receive two injections of the rMVA-HIV vaccine and the rFPV-HIV vaccine	Biological: rMVA-HIV (env/gag [TBC-M358] + tat/rev/nef-RT [TBC-M335)]) Recombinant experimental therapeutic vaccine using the modified vaccinia Ankara vector given at study entry and Week 4 Biological: rFPV-HIV (env/gag [TBC-F357] + tat/rev/nef-RT [TBC-F349]) Recombinant experimental therapeutic vaccine using fowlpox vector given at Weeks 8 and 24

Detailed Description:

By helping to control viral replication, HAART has dramatically improved the prognosis for HIV infected individuals. However, because of extensive side effects, some of which may be acute and life-threatening, many patients find it difficult to tolerate a HAART regimen. HAART-associated long-term morbidity or mortality contribute to this difficulty. Administering an HIV therapeutic vaccine might allow HIV infected individuals to delay or interrupt treatment, avoiding the side effects associated with antiretroviral exposure. This study will evaluate the safety of two injections of two recombinant therapeutic vaccines in HIV infected young adults who are currently on stable HAART.

This study will last 72 weeks. All participants will receive two rMVA vaccines (env/gag and tat/rev/nef-RT) at study entry and at Week 4 and two rFPV vaccines (env/gag and tat/rev/nef-RT) at Weeks 8 and 24. Safety will be assessed immediately after each immunization and at 1 hour and 48 hours postimmunization. There will be 16 study visits over 72 weeks. A physical exam, blood collection, and administration of an adherence module will occur at most visits. An electrocardiogram (ECG) will occur at study entry and Weeks 2 and 10. Urine collection will occur at study entry and Weeks 4, 8, and 24.

Eligibility


Ages Eligible for Study:	18 Years to 24 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

HIV-1 infected
CD4 count of 350 cells/mm3 or greater
If hepatitis B or C infected, infection must be chronic and stable
Normal electrocardiogram (ECG)
On stable HAART consisting of at least 3 different antiretrovirals from 2 different classes AND with a viral load of less than 100 copies/ml for at least 6 months prior to study entry
Willing to use acceptable forms of contraception. Females enrolled in the study must use contraception for at least 21 days prior to first vaccination until the last study visit. Males enrolled in the study must use a condom from the first vaccination until one month after the last vaccination.
Willing to follow all study requirements
Available for follow-up for the duration of the study

Exclusion Criteria:

History of allergic reaction to eggs or egg products
Known hypersensitivity to vaccine components
Chemotherapy for active cancer in the 12 months prior to study entry
Prior vaccination with any HIV-1 vaccine
Prior vaccination against smallpox
Prior vaccinia immunization
Any immunization within 1 month of study screening
History of or known active heart disease including myocardial infarction, angina pectoris, congestive heart failure, cardiomyopathy, pericarditis, stroke or transient ischemic attack, chest pain or shortness of breath with activity such as walking upstairs, mitral valve prolapse, or other heart conditions under a doctor's care
Immunomodulatory agents, gamma globulin, or investigational agents within 6 months of study entry
Systemic steroids, including nonprescription street steroids, within 6 months of study entry
Documented or suspected serious bacterial infection, metabolic illness, cancer, or immediate life-threatening condition
Any clinically significant diseases other than HIV infection or clinically significant findings during study screening that, in the investigator's opinion, may interfere with the study
Current alcohol or drug abuse that, in the investigator's opinion, may interfere with the study
Pregnancy or breastfeeding

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00107549

Locations


United States, California
Children's Hospital Los Angeles NICHD CRS
Los Angeles, California, United States, 90027
Usc La Nichd Crs
Los Angeles, California, United States, 90033
United States, Colorado
Univ. of Colorado Denver NICHD CRS
Aurora, Colorado, United States, 80218-1088
United States, Illinois
Chicago Children's CRS
Chicago, Illinois, United States, 60614
United States, Maryland
Univ. of Maryland Baltimore NICHD CRS
Baltimore, Maryland, United States
United States, New York
Columbia IMPAACT CRS
New York, New York, United States
United States, North Carolina
DUMC Ped. CRS
Durham, North Carolina, United States
United States, Tennessee
St. Jude/UTHSC CRS
Memphis, Tennessee, United States, 38105-2794
Puerto Rico
Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS
San Juan, Puerto Rico

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Investigators


Study Chair:	Coleen K. Cunningham, MD	Pediatric Infectious Diseases, Duke University

More Information

Publications:

Caputo A, Gavioli R, Ensoli B. Recent advances in the development of HIV-1 Tat-based vaccines. Curr HIV Res. 2004 Oct;2(4):357-76. Review.

Cosma A, Nagaraj R, Bühler S, Hinkula J, Busch DH, Sutter G, Goebel FD, Erfle V. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine. 2003 Dec 8;22(1):21-9.

Kent SJ, Zhao A, Best SJ, Chandler JD, Boyle DB, Ramshaw IA. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J Virol. 1998 Dec;72(12):10180-8.

Mwau M, Cebere I, Sutton J, Chikoti P, Winstone N, Wee EG, Beattie T, Chen YH, Dorrell L, McShane H, Schmidt C, Brooks M, Patel S, Roberts J, Conlon C, Rowland-Jones SL, Bwayo JJ, McMichael AJ, Hanke T. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol. 2004 Apr;85(Pt 4):911-9.

Pancharoen C, Ananworanich J, Thisyakorn U. Immunization for persons infected with human immunodeficiency virus. Curr HIV Res. 2004 Oct;2(4):293-9. Review.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Shiu C, Cunningham CK, Greenough T, Muresan P, Sanchez-Merino V, Carey V, Jackson JB, Ziemniak C, Fox L, Belzer M, Ray SC, Luzuriaga K, Persaud D; Pediatric AIDS Clinical Trials Group P1059 Team. Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretroviral therapy. J Virol. 2009 Oct;83(19):9731-42. doi: 10.1128/JVI.00570-09. Epub 2009 Jul 15.


Responsible Party:	National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:	NCT00107549 History of Changes
Other Study ID Numbers:	P1059 10051 ( Registry Identifier: DAIDS ES Registry Number ) PACTG P1059
Study First Received:	April 5, 2005
Last Updated:	May 17, 2012

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):


Treatment Experienced HIV Therapeutic Vaccine

Additional relevant MeSH terms:


HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral	Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Vaccines Immunologic Factors Physiological Effects of Drugs

ClinicalTrials.gov processed this record on July 17, 2017